Novel hand, foot and mouth disease (HFMD) therapeutics

Hand, foot and mouth disease (HFMD) infects millions of children around the world each year and can present as a mild disease through to severe neurological disease. Griffith University's Institute for Glycomics has developed potent small molecule inhibitors for HFMD.

Unique selling point/competitive advantage

There are currently no drugs on the market to treat mild or severe HFMD. The lead drug candidate from Griffith University's Institute for Glycomics inhibits the virus at clinically relevant nanomolar concentrations and is an order of magnitude more potent than the best published inhibitor.

The research team has extensive drug discovery, translation and commercialisation expertise.

Investment or collaboration opportunities

Griffith University's Institute for Glycomics is seeking a company partner to co-develop their carbohydrate-based small molecule candidates through lead optimisation and preclinical stages.

An option to an exclusive global licence is available.

Intellectual property rights

Griffith University has proprietary rights for composition of matter and a patented synthetic method to prepare lead molecules.

Contact

Dr Chris Davis
General Manager
Phone: +61 7 555 27033
Email: chris.davis@griffith.edu.au

More information

Visit Griffith University - Institute for Glycomics for more information for investors.

Also consider...

• Read about other investment-ready opportunities.
• Discover other collaboration opportunities.